Astrana Health price target lowered to $46 from $50 at Truist

Truist analyst Jailendra Singh lowered the firm’s price target on Astrana Health (ASTH) to $46 from $50 and keeps a Buy rating on the shares. The firm is updating its model to reflect the company’s Q4 earnings release and 2025 outlook, the analyst tells investors in a research note. Truist adds that its valuation represents a slight premium to Astrana’s next-12-months enterprise value to EBITDA average multiple over the last year and gives credit to its recent history of outperformance relative to the value-based care industry as a whole.